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have shown that prokineticin receptor-1 (PKR1) signaling contributes to car-
diomyocyte survival or repair in myocardial infarction. Here, we discovered
the first non-peptidic PKR1 agonists and examined their effects in mice model
of heart diseases.
Methods and results: Herein we identify a selective PKR1 agonist both in
vitro and in vivo, utilizing GPCR structure-based virtual screening approach.
High Throughput Docking was carried out by GOLD using homology model
of PKR1. Asinex gold collection 3D chemical databese (250,000 compounds)
was screened by the docking protocol. We provided a strategy with a high
potential for in silico identifying one agonist hit. We present here IS20, the
first synthetic PKR1 agonist that induces angiogenesis in the presence of
PKR1 on the endothelial cells seeded on matrigel. IS20 reduced doxorubicin
cytotoxicity in H9C2 cells. IS20 promotes mouse epicardial progenitor cell
differentiation into endothelial cells. In vivo IS20 activates Akt in mice heart.
IS20 treatment of mice after coronary ligation reduces mortality by 30%.
Conclusion: This study identifies a non-peptidic PKR1 agonist as thera-
peutic target holding promise for treatment of heart diseases.
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Lack of post-ischemic revascularization is a major complication in diabetic
patients. The kallikrein-kinin system (KKS) could play a role in post-ischemic
neovascularization in non-diabetic conditions. The aim of this study was to
potentialized the post-ischemic neovascularization process in diabetic mice via
specific activation of bradykinin receptors (B1R or B2R) of KKS.
Hindlimb ischemia was induced in normo or hyperglycemic mice by liga-
tion of the right femoral artery. Mice were then treated or not with specific
B1R or B2R agonists (720nmol/kg.d-1). Fourteen days after ischemia, neovas-
cularization was analyzed using angiography, capillary density analysis, foot
blood perfusion measurement and biochemistry. At the end of treatment, vas-
cular and capillary density and skin foot blood flow were significantly
decreased in diabetic condition. In contrast, treatment of diabetic mice with
the B1R or B2R agonist restored post-ischemic neovascularization process to
normal levels of vascular density (+45% for B1R, p<0.01 and 40% for B2R
p<0.01), capillary density (+64% for B1R, p<0.01 and 66% for B2R, p<0.01)
and foot blood perfusion (40% for B1R; p<0.01 and 30% for B2R, p<0.01)
when compared with untreated diabetic mice. These beneficial effects were
associated with an increase in macrophages infiltration in ischemic tissue and
an increase in VEGF protein levels in gastrocnemius muscle. Moreover, in
diabetic mice, 7 days of treatment with B2R agonist, but not B1R agonist, sig-
nificantly increased MCP-1 mRNA expression in muscle (+95%, p<0,01),
MCP-1 level in plasma (+18.5%, p<0.05) and number of circulating mono-
cytes.
KKS modulation via B1R or B2R agonist can restore post-ischemic neo-
vascularization in diabetic mice and may represent a new therapeutic strategy
in this context.
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Red wine polyphenols compounds (RWPC) are known to protect against
deleterious effects of cardiac and cerebral ischemia. However, they exert dif-
ferent effect depending on the dose on post-ischemic neovascularisation. Low
dose (0.2mg/kg/d) promotes angiogenesis, whereas high dose (20mg/kg/d) has
anti-angiogenic property. The vascular effect of RWPC is mediated through
the activation of a redox-sensitive pathway, mitochondrial biogenesis and the
activation of α isoform of the estrogen receptor (ERα). Here we evaluate the
implication of ERα on angiogenic properties of RWPC. Using ovariectomized
mice lacking ERα treated with high dose of RWPC after hindlimb ischemia,
we examined blood flow reperfusion, vascular density, nitric oxide (NO) pro-
duction, expression and activation of proteins involved in angiogenic process
(eNOS, cav-1, VEGF) and muscle energy sensing network proteins (Sirt-1,
AMPK and PGC-1). High dose of RWPC treatment reduced both blood flow
and vascular density in muscles of mice expressing ERα. These effects were
associated with reduced NO production resulting from diminished activity of
eNOS. Surprisingly, high dose of RWPC increased blood flow and capillary
density in mice lacking ERα. This effect is accompanied with increased NO
pathway and production as well as VEGF expression. Interestingly, RWPC
was able to activate Sirt-1, AMPK and PGC-1 in hindlimb from both strains.
Altogether, the results highlight a pro-angiogenic property of RWPC via an
ERα-independent mechanism that is associated with an up-regulation of
energy sensing network proteins of the Sirt-1, PGC-1 network. This study
depicts a novel way by which polyphenols may represent a therapeutic
approach to treat pathologies associated with failed vascularisation.
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